ZBH Stock Price Zimmer Biomet Holdings Inc Stock Quote U.S.: NYSE

We also see little to shift our thinking on Zimmer Biomet’s wide economic moat, which primarily stems from strong switching costs among surgeons. The technique has proven to be very useful for finding positive surprises. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest.

• Compare
  ZBH’s historical performance
  against its industry peers and the overall market.
• For more insight on analysts targets of ZBH, see our ZBH price target page.
• Zimmer Biomet recently completed its planned spin-off procedure of the dental & spine arm.
• Morgan Stanley on Monday downgrades Crowdstrike (CRWD) to equal weight, from overweight.
• Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%.
• Stocks are set to open the new week slightly higher, with the S&P 500 up 0.3% in premarket trading.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Zimmer Biomet Holdings Inc is a medical technology company that designs, develops and manufactures a wide range of orthopedic and musculoskeletal products. With headquarters in Warsaw, Indiana, the company was formed in 2015 after the merger of Zimmer Holdings and Biomet Inc, two of the world’s leading companies in the orthopedic industry. Zimmer Biomet’s mission is to help people alleviate pain, regain mobility and improve the quality of life for patients worldwide.

Earnings and Valuation

Securities products offered by Open to the Public Investing are not FDIC insured. Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits. First quarter net sales of $1.831 billion increased 10.1% and 13.2% on a constant currency1 basis First quarter diluted earnings per share were $1.11; adjusted1 diluted earnings per share were $1.89 C… Second quarter net sales of $1.870 billion increased 4.9% and 6.0% on a constant currency1 basis Second quarter diluted earnings per share were $1.00; adjusted1 diluted earnings per share were $1.82 C… Jefferies on Monday raises its price target on Club name Pioneer Natural Resources (PXD) to $265 a share, from $245, while reiterating a hold rating on the stock. Oil prices were little changed Monday, with West Texas Intermediate crude holding slightly below $80 per barrel.

Some better-ranked stocks in the broader medical space are Haemonetics HAE, Quanterix QTRX and SiBone SIBN. The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. Click the link below and we’ll send you MarketBeat’s guide to pot stock investing and which pot companies show the most promise.

Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products. Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors. Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks.

Per-Share Earnings, Actuals and Estimates

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Finally, changes in consumer preferences and healthcare trends could impact demand for Zimmer Biomet’s products.

The company’s leadership team is led by President and CEO Bryan Hanson, who has been in his current role since 2017. Hanson has over 30 years of experience in the medical device industry and has held various executive positions in leading medical device EverFX companies. Additionally, Zimmer Biomet’s executive team includes Chief Financial Officer Suketu Upadhyay and Chief Operating Officer Ivan Tornos. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

Zimmer Biomet Holdings Inc. stock outperforms market on strong trading day

Zimmer Biomet’s (ZBH Quick QuoteZBH – Free Report) strategic spin-off of the non-core dental and spine business and stabilizing market trends bolster our confidence in the stock. Yet, factors like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations continue to adversely impact Zimmer Biomet’s sales. Boeing (BA) is reportedly planning to restart deliveries of its 737 Max jets to China after four years, according to Bloomberg. Following the news, TD Cowen raises its price target on Boeing to $260 a share, from $255, while maintaining an outperform rating on the stock. Meanwhile, China’s foreign ministry on Monday announces inbound travelers won’t need a Covid-19 antigen test. Zimmer Biomet recently completed its planned spin-off procedure of the dental & spine arm.

• These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks.
• Recent stocks from this report have soared up to +178.7% in 3 months – this month’s picks could be even better.
• We’re surprised and disappointed by the news that Bryan Hanson has stepped down as chief executive officer at Zimmer Biomet to take a comparable position at 3M’s impending healthcare spinoff.
• The news follows Danaher’s announcement late Friday that the upcoming separation of its environmental and applied solutions business will be completed on Sept. 30 via a tax-free spin-off.
• The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zimmer Biomet’s ZBH strategic spin-off of the non-core dental and spine business and stabilizing market trends bolster our confidence in the stock. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered.

Top Ranked Technology Stocks Charging Higher into Year End

Company’s seventh sustainability report highlights progress in product quality & safety, environmental impact improvements and diversity, equity and inclusion initiatives WARSAW, Ind. , May 2, 2023 /P… Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. Compare
ZBH’s historical performance
against its industry peers and the overall market. Morningstar analysts hand-select direct competitors or comparable companies to
provide context on the strength and durability of ZBH’s
competitive advantage.

The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Truist on Monday upgrades consumer goods name Church & Dwight (CHD) to buy, from hold, while raising its price target to $105 a share, from $95. Analysts at Truist argue that the company and its categories “are largely out of the woods from the post-pandemic reversion.” Estimates for Quanterix’s 2023 loss per share have narrowed from $1.19 to 97 cents in the past 30 days. Shares of the company have increased 167.5% in the past year against the industry’s decline of 1.7%.

The news follows Danaher’s announcement late Friday that the upcoming separation of its environmental and applied solutions business will be completed on Sept. 30 via a tax-free spin-off. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use, please see disclaimer. Earnings estimates for Haemonetics have increased from $3.56 to $3.74 in 2023 and from $3.96 to $4.07 in 2024 in the past 30 days. You can see the complete list of today’s Zacks #1 Rank stocks here.

Zimmer Biomet Holdings Inc. stock underperforms Tuesday when compared to competitors

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns. You should consult your legal, tax, or financial advisors before making any financial decisions. This material is not intended as a recommendation, offer, or solicitation to purchase or sell securities, open a brokerage account, or engage in any investment strategy. The orthopedic industry is highly competitive, with a few major players dominating the market. Zimmer Biomet is one of the largest companies in the industry, with a strong presence in the joint reconstruction, spine, dental, and sports medicine markets.

Please see Open to the Public Investing’s Fee Schedule to learn more. JSI and Jiko Bank are not affiliated with Public Holdings, Inc. (“Public”) or any of its subsidiaries. None of these entities provide legal, tax, or accounting advice. One of the most significant risks facing Zimmer Biomet is the potential for regulatory changes that could impact the industry. Changes in regulatory requirements could increase the costs and time required to bring new products to market, affecting Zimmer Biomet’s ability to innovate and compete. In addition, insurance and hospital reimbursement policy changes could also impact the demand for Zimmer Biomet’s products.

This average price target has increased by 2.91% over the past month. Zimmer Biomet’s stock is owned by a number of retail and institutional investors. Insiders that own company stock include Arthur J Higgins, Arthur J Higgins, Betsy J Bernard, Chad F Phipps, Michael W Michelson, Robert Hagemann, Sang Yi, Sreelakshmi Kolli and Zuilen Wilfred Van. https://investmentsanalysis.info/ Another risk facing Zimmer Biomet is the potential for increased competition. While the company is one of the most significant players in the orthopedic industry, it faces competition from other established companies and new entrants. To maintain its market position, Zimmer Biomet must continue to innovate and invest in research and development.